Bioarchitech
Bioarchitech is pioneering in cancer immunotherapy by mining the genetic code of viruses to develop multifunctional therapies that kill cancer cells and induce immunity. Their mission is to innovate cancer treatment through advanced viral and RNA-based therapies, aiming to treat cancer at every stage and improve patient outcomes.
Industries
Nr. of Employees
small (1-50)
Bioarchitech
Wood Centre for Innovation, Quarry Road, Headington, Oxford, OX3 8SB
Products
Systemic oncolytic viral therapy with immune-checkpoint-blocking payload
An intravenously administered replication-competent viral therapy engineered to replicate selectively in tumour cells and express a single-domain antibody targeting an immune 'don't eat me' signal to enhance tumour phagocytosis and T cell responses.
Intratumoural self-amplifying RNA neo-adjuvant immunotherapy
A self-amplifying RNA therapeutic administered by intratumoural injection intended to induce rapid immunogenic cell death and in situ tumour vaccination prior to surgery.
Systemic oncolytic viral therapy with immune-checkpoint-blocking payload
An intravenously administered replication-competent viral therapy engineered to replicate selectively in tumour cells and express a single-domain antibody targeting an immune 'don't eat me' signal to enhance tumour phagocytosis and T cell responses.
Intratumoural self-amplifying RNA neo-adjuvant immunotherapy
A self-amplifying RNA therapeutic administered by intratumoural injection intended to induce rapid immunogenic cell death and in situ tumour vaccination prior to surgery.
Services
Collaborative preclinical development including viral payload optimisation, in vivo efficacy testing, and translational assay support delivered via academic and industry partnerships.
Collaborative projects and student-industry placements to investigate and develop alternative mRNA delivery vehicles and lipid nanoparticle technologies for improved tumour targeting.
Collaborative preclinical development including viral payload optimisation, in vivo efficacy testing, and translational assay support delivered via academic and industry partnerships.
Collaborative projects and student-industry placements to investigate and develop alternative mRNA delivery vehicles and lipid nanoparticle technologies for improved tumour targeting.
Expertise Areas
- Oncolytic virotherapy
- Self-amplifying RNA therapeutics
- Viral transgene payload engineering
- Preclinical in vivo efficacy and metastasis models
Key Technologies
- Oncolytic viral vectors (vaccinia-based)
- Self-amplifying RNA (saRNA)
- Single-domain antibody (sdAb) expression
- Intratumoural delivery
News & Updates
Bioarchitech was named Startup Spotlight 2025 winner at ChinaBio in Shanghai for their novel RNA therapeutic BA-R166.
Bioarchitech participated in BioTrinity, showcasing their work and connecting with innovators, investors, and collaborators.
Andri Vasou, Head of Platform Development, spoke at an International Women's Day event at Lady Margaret Hall, Oxford.
Bioarchitech filed a UK patent application for their lead candidate virus BA-V151, targeting immune resistance mechanisms in cancer.
Bioarchitech's founders presented at JPM2025, showcasing their cancer immunotherapy platform and lead candidate BA-V151.
Bioarchitech filed another UK patent application, strengthening their intellectual property portfolio.
Bioarchitech was named Startup Spotlight 2025 winner at ChinaBio in Shanghai for their novel RNA therapeutic BA-R166.
Bioarchitech participated in BioTrinity, showcasing their work and connecting with innovators, investors, and collaborators.
Andri Vasou, Head of Platform Development, spoke at an International Women's Day event at Lady Margaret Hall, Oxford.
Bioarchitech filed a UK patent application for their lead candidate virus BA-V151, targeting immune resistance mechanisms in cancer.
Bioarchitech's founders presented at JPM2025, showcasing their cancer immunotherapy platform and lead candidate BA-V151.
Bioarchitech filed another UK patent application, strengthening their intellectual property portfolio.